anti-CD19 CAR T cell therapy for Desensitization of an anti-HLA-hyperimmunized waitlisted kidney transplant candidate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038215

Enrollment

Registered

2025-10-21

Start date

2024-08-30

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organtransplantation

Interventions

Group 1: anti-CD19 CAR T (KYV-101) Therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: High-grade HLA immunization, end-stage renal failure, no prospect of a donor organ due to immunization level

Exclusion criteria

Exclusion criteria: relevant further comorbidties

Design outcomes

Primary

Measure	Time frame
successful kidney transplantation with adequate graft function for 12 months thereafter	—

Secondary

Measure	Time frame
immunological response parameters	—

Countries

Germany

Contacts

Public ContactEva Schrezenmeier

Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin Charité - Universitätsmedizin Berlin

eva-vanessa.schrezenmeier@charite.de+491721519645

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026